Long-term control by immune checkpoint inhibitors in a lung cancer patient with chronic kidney disease
Nivolumab and ipilimumab regimen might become one of the options for NSCLC patients with CKD. This report could provide some suggestions for the treatment of future patients who might experience a similar course of the therapy.
Authors
- Toshihiro Shiozawa (ORCID: https://orcid.org/0000-0002-5869-8494)
- Hiroaki Matsumoto (ORCID: https://orcid.org/0000-0003-0568-1258)
- Yosuke Maezawa
- Gen Ohara
- Hironori Masuko (ORCID: https://orcid.org/0000-0002-5917-7973)
- Hiroaki Satoh (ORCID: https://orcid.org/0000-0002-1561-1723)
Publication Details
- Journal
- Klinicka onkologie
- Published
- 2024-10-14
- DOI
- https://doi.org/10.48095/ccko2024375
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.57